Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 1/2020

01.06.2020 | Methotrexat | Leitlinien

Management der frühen rheumatoiden Arthritis

Interdisziplinäre Leitlinie

verfasst von: Prof. Dr. M. Schneider, G. Baseler, O. Funken, S. Heberger, U. Kiltz, P. Klose, K. Krüger, J. Langhorst, W. Mau, R. Oltman, B. Richter, S. Seitz, P. Sewerin, R. Tholen, C. Weseloh, Univ.-Prof. Dr. M. Witthöft, C. Specker

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Auszug

Entwicklungsstufe: S3 …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zink A, Albrecht K (2016) Wie häufig sind muskuloskeletale Erkrankungen in Deutschland? Z Rheumatol 75:346–353PubMedCrossRef Zink A, Albrecht K (2016) Wie häufig sind muskuloskeletale Erkrankungen in Deutschland? Z Rheumatol 75:346–353PubMedCrossRef
2.
Zurück zum Zitat Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prävalenz der rheumatoiden arthritis in deutschland auf basis von Kassendaten. Z Rheumatol 75:819–827PubMedCrossRef Hense S, Luque Ramos A, Callhoff J, Albrecht K, Zink A, Hoffmann F (2016) Prävalenz der rheumatoiden arthritis in deutschland auf basis von Kassendaten. Z Rheumatol 75:819–827PubMedCrossRef
3.
Zurück zum Zitat Carmona L, Cross M, Williams B, Lassere M, March L (2010) Rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 24:733–745CrossRef Carmona L, Cross M, Williams B, Lassere M, March L (2010) Rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 24:733–745CrossRef
5.
Zurück zum Zitat Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 65:71–77CrossRef Crowson CS, Matteson EL, Davis JM, Gabriel SE (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res 65:71–77CrossRef
6.
Zurück zum Zitat Hedström AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a swedish population-based case–control study. Eur J Epidemiol 33:415–423PubMedPubMedCentralCrossRef Hedström AK, Stawiarz L, Klareskog L, Alfredsson L (2018) Smoking and susceptibility to rheumatoid arthritis in a swedish population-based case–control study. Eur J Epidemiol 33:415–423PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum 62:1576–1582PubMedPubMedCentralCrossRef Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: Results from olmsted county, minnesota, 1955–2007. Arthritis Rheum 62:1576–1582PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Pedersen JK, Svendsen AJ, Hørslev-Petersen K (2007) Incidence of rheumatoid arthritis in the southern part of denmark from 1995 to 2001. TORJ 1:18–23PubMedCrossRefPubMedCentral Pedersen JK, Svendsen AJ, Hørslev-Petersen K (2007) Incidence of rheumatoid arthritis in the southern part of denmark from 1995 to 2001. TORJ 1:18–23PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al (2017) 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959PubMedCrossRef Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM et al (2017) 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 76:948–959PubMedCrossRef
10.
Zurück zum Zitat Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al (2000) How does functional disability in early rheumatoid arthritis (ra) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early ra study (eras). Rheumatology 39:603–611PubMedCrossRef Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al (2000) How does functional disability in early rheumatoid arthritis (ra) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early ra study (eras). Rheumatology 39:603–611PubMedCrossRef
11.
Zurück zum Zitat Verstappen SM (2013) Outcomes of early rheumatoid arthritis—the who icf framework. Baillieres Best Pract Res Clin Rheumatol 27:555–570CrossRef Verstappen SM (2013) Outcomes of early rheumatoid arthritis—the who icf framework. Baillieres Best Pract Res Clin Rheumatol 27:555–570CrossRef
12.
Zurück zum Zitat Nikiphorou E, Norton S, Carpenter L, Dixey J, Walsh AD, Kiely P et al (2017) Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. Arthritis Care Res 69:21–27CrossRef Nikiphorou E, Norton S, Carpenter L, Dixey J, Walsh AD, Kiely P et al (2017) Secular changes in clinical features at presentation of rheumatoid arthritis: Increase in comorbidity but improved inflammatory states. Arthritis Care Res 69:21–27CrossRef
13.
Zurück zum Zitat Listing J, Kekow J, Manger B, Burmester G‑R, Pattloch D, Zink A et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, tnfα inhibitors and rituximab. Ann Rheum Dis 74:415–421PubMedCrossRef Listing J, Kekow J, Manger B, Burmester G‑R, Pattloch D, Zink A et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, tnfα inhibitors and rituximab. Ann Rheum Dis 74:415–421PubMedCrossRef
14.
Zurück zum Zitat Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313PubMedCrossRef Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313PubMedCrossRef
15.
Zurück zum Zitat Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF (2010) Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 62:362–370CrossRef Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF (2010) Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 62:362–370CrossRef
16.
Zurück zum Zitat Lindqvist E, Saxne T, Geborek P, Eberhardt K (2002) Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61:1055–1059PubMedPubMedCentralCrossRef Lindqvist E, Saxne T, Geborek P, Eberhardt K (2002) Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 61:1055–1059PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1994) The severity of rheumatoid arthritis: a 6‑year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620–1625PubMed van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1994) The severity of rheumatoid arthritis: a 6‑year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620–1625PubMed
18.
Zurück zum Zitat Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44:1033–1042PubMedCrossRef Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP et al (2001) Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 44:1033–1042PubMedCrossRef
19.
Zurück zum Zitat Bukhari Ma S, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM et al (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53PubMedCrossRef Bukhari Ma S, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM et al (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48:46–53PubMedCrossRef
20.
Zurück zum Zitat Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al (2005) Anti-sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603PubMedPubMedCentralCrossRef Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al (2005) Anti-sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:R592–R603PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Gorman JD (2006) Smoking and rheumatoid arthritis: another reason to just say no. Arthritis Rheum 54:10–13PubMedCrossRef Gorman JD (2006) Smoking and rheumatoid arthritis: another reason to just say no. Arthritis Rheum 54:10–13PubMedCrossRef
22.
Zurück zum Zitat Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L et al (2005) Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204PubMedPubMedCentralCrossRef Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L et al (2005) Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 64:1199–1204PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C, group Bs (2006) Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 65:601–606PubMedCrossRef Nyhäll-Wåhlin BM, Jacobsson LTH, Petersson IF, Turesson C, group Bs (2006) Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 65:601–606PubMedCrossRef
24.
Zurück zum Zitat Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736PubMedPubMedCentralCrossRef Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef
26.
Zurück zum Zitat Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP (2013) The protective effect of alcohol on developing rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology 52:856–867PubMedCrossRef Scott IC, Tan R, Stahl D, Steer S, Lewis CM, Cope AP (2013) The protective effect of alcohol on developing rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology 52:856–867PubMedCrossRef
27.
Zurück zum Zitat Symmons DPM (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707–722CrossRef Symmons DPM (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707–722CrossRef
28.
Zurück zum Zitat van der Helm-van Mil AHM, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440PubMedCrossRef van der Helm-van Mil AHM, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56:433–440PubMedCrossRef
29.
Zurück zum Zitat van der Helm-van Mil AHM, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al (2008) Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247PubMedCrossRef van der Helm-van Mil AHM, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR et al (2008) Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58:2241–2247PubMedCrossRef
30.
Zurück zum Zitat Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365PubMedCrossRef Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365PubMedCrossRef
31.
Zurück zum Zitat Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an elisa using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180PubMedPubMedCentralCrossRef Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D et al (2004) Autoantibodies recognizing citrullinated rat filaggrin in an elisa using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173–180PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Wolfe F, Zwillich SH (1998) The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072–1082PubMedCrossRef Wolfe F, Zwillich SH (1998) The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072–1082PubMedCrossRef
33.
Zurück zum Zitat van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the leiden early arthritis clinic and espoir cohorts. Ann Rheum Dis 74:806–812PubMedCrossRef van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the leiden early arthritis clinic and espoir cohorts. Ann Rheum Dis 74:806–812PubMedCrossRef
34.
Zurück zum Zitat Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90PubMedCrossRef Emery P (1995) Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 34(Suppl 2):87–90PubMedCrossRef
35.
Zurück zum Zitat Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS (1998) Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53:13–19PubMed Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS (1998) Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53:13–19PubMed
36.
Zurück zum Zitat Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771–1774PubMedCrossRef Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48:1771–1774PubMedCrossRef
37.
Zurück zum Zitat O’Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283–285PubMedCrossRef O’Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283–285PubMedCrossRef
38.
Zurück zum Zitat Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297PubMedPubMedCentralCrossRef Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS (2002) Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61:290–297PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588PubMedCrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588PubMedCrossRef
40.
Zurück zum Zitat Radner H, Neogi T, Smolen JS, Aletaha D (2014) Performance of the 2010 acr/eular classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73:114–123PubMedCrossRef Radner H, Neogi T, Smolen JS, Aletaha D (2014) Performance of the 2010 acr/eular classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 73:114–123PubMedCrossRef
41.
Zurück zum Zitat Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: Results from a primary care-based inception cohort of patients. Rheumatology 41:246–252PubMedCrossRef Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: Results from a primary care-based inception cohort of patients. Rheumatology 41:246–252PubMedCrossRef
42.
Zurück zum Zitat Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of ra in the light of the acr/eular 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72:590–595PubMedCrossRef Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AH (2013) Defining erosive disease typical of ra in the light of the acr/eular 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 72:590–595PubMedCrossRef
43.
Zurück zum Zitat Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, c‑reactive protein, or rheumatoid factor are normal at presentation in 35 %–45 % of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from finland and the united states. J Rheumatol 36:1387–1390PubMedCrossRef Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, c‑reactive protein, or rheumatoid factor are normal at presentation in 35 %–45 % of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from finland and the united states. J Rheumatol 36:1387–1390PubMedCrossRef
44.
Zurück zum Zitat Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165PubMedCrossRef Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB et al (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165PubMedCrossRef
45.
Zurück zum Zitat Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M et al (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193PubMedCrossRef Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M et al (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193PubMedCrossRef
46.
Zurück zum Zitat Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511PubMedCrossRef Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511PubMedCrossRef
47.
Zurück zum Zitat Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE et al (2010) Diagnostic value of anti-mcv antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69:730–732PubMedCrossRef Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort EI, Toes RE et al (2010) Diagnostic value of anti-mcv antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 69:730–732PubMedCrossRef
48.
Zurück zum Zitat Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008PubMed Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008PubMed
49.
Zurück zum Zitat Lee YH, Bae SC, Song GG (2015) Diagnostic accuracy of anti-mcv and anti-ccp antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 74:911–918PubMedCrossRef Lee YH, Bae SC, Song GG (2015) Diagnostic accuracy of anti-mcv and anti-ccp antibodies in rheumatoid arthritis: a meta-analysis. Z Rheumatol 74:911–918PubMedCrossRef
50.
Zurück zum Zitat Luime JJ, Colin EM, Hazes JMW, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337–344PubMedCrossRef Luime JJ, Colin EM, Hazes JMW, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337–344PubMedCrossRef
51.
Zurück zum Zitat Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45PubMedCrossRef Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45PubMedCrossRef
52.
Zurück zum Zitat Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 69:345–351PubMedCrossRef Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 69:345–351PubMedCrossRef
53.
Zurück zum Zitat van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EWN, Stoeken-Rijsbergen G, Huizinga TWJ et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef van der Linden MPM, van der Woude D, Ioan-Facsinay A, Levarht EWN, Stoeken-Rijsbergen G, Huizinga TWJ et al (2009) Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60:2232–2241PubMedCrossRef
54.
Zurück zum Zitat Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808PubMedCrossRef Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808PubMedCrossRef
55.
Zurück zum Zitat Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al (2010) Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152:456–464; W155–66PubMedCrossRef Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al (2010) Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152:456–464; W155–66PubMedCrossRef
56.
Zurück zum Zitat Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and igm rheumatoid factors. Rheumatology 41:809–814PubMedCrossRef Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and igm rheumatoid factors. Rheumatology 41:809–814PubMedCrossRef
57.
Zurück zum Zitat Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by iga-rf at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRef Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G et al (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by iga-rf at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRef
58.
Zurück zum Zitat Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do acpa discriminate and predict ra in the general population: a study based on 12 590 population-representative swedish twins. Ann Rheum Dis 76:119–125PubMedCrossRef Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do acpa discriminate and predict ra in the general population: a study based on 12 590 population-representative swedish twins. Ann Rheum Dis 76:119–125PubMedCrossRef
60.
Zurück zum Zitat Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef
61.
Zurück zum Zitat Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749PubMedPubMedCentralCrossRef Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93PubMedCrossRef van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 4:87–93PubMedCrossRef
63.
Zurück zum Zitat van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef
64.
Zurück zum Zitat Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef
65.
Zurück zum Zitat Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef
66.
Zurück zum Zitat Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al (2009) Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: Results from the nor-veac cohort. Arthritis Res Ther 11:R146PubMedPubMedCentralCrossRef Mjaavatten MD, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K et al (2009) Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: Results from the nor-veac cohort. Arthritis Res Ther 11:R146PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217PubMedCrossRef Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217PubMedCrossRef
68.
Zurück zum Zitat Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-ccp antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the swedish tira project). Ann Rheum Dis 63:1085–1089PubMedPubMedCentralCrossRef Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-ccp antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the swedish tira project). Ann Rheum Dis 63:1085–1089PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using dmards and very low doses of glucocorticoids. Clin Rheumatol 26:1111–1118PubMedCrossRef Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: A two year prospective study after a structured therapeutic strategy using dmards and very low doses of glucocorticoids. Clin Rheumatol 26:1111–1118PubMedCrossRef
70.
Zurück zum Zitat Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M et al (2002) Very recent onset arthritis—clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278–2287PubMed Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M et al (2002) Very recent onset arthritis—clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278–2287PubMed
71.
Zurück zum Zitat Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al (2009) Mri bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (cimestra). Ann Rheum Dis 68:384–390PubMedCrossRef Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG et al (2009) Mri bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (cimestra). Ann Rheum Dis 68:384–390PubMedCrossRef
72.
Zurück zum Zitat Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA et al (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 34:839–847PubMed Joshua F, Lassere M, Bruyn GA, Szkudlarek M, Naredo E, Schmidt WA et al (2007) Summary findings of a systematic review of the ultrasound assessment of synovitis. J Rheumatol 34:839–847PubMed
73.
Zurück zum Zitat Østergaard M, Pedersen SJ, Døhn UM (2008) Imaging in rheumatoid arthritis—status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 22:1019–1044PubMedCrossRef Østergaard M, Pedersen SJ, Døhn UM (2008) Imaging in rheumatoid arthritis—status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 22:1019–1044PubMedCrossRef
74.
Zurück zum Zitat Joshua F, Edmonds J, Lassere M (2006) Power doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36:99–108PubMedCrossRef Joshua F, Edmonds J, Lassere M (2006) Power doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36:99–108PubMedCrossRef
75.
Zurück zum Zitat Strunk J, Backhaus M, Schmidt W, Kellner H (2010) Color doppler sonography for investigation of peripheral joints and ligaments. Z Rheumatol 69:164–170PubMedCrossRef Strunk J, Backhaus M, Schmidt W, Kellner H (2010) Color doppler sonography for investigation of peripheral joints and ligaments. Z Rheumatol 69:164–170PubMedCrossRef
77.
Zurück zum Zitat Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al (2003) Omeract rheumatoid arthritis magnetic resonance imaging studies. Core set of mri acquisitions, joint pathology definitions, and the omeract ra-mri scoring system. J Rheumatol 30:1385–1386PubMed Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al (2003) Omeract rheumatoid arthritis magnetic resonance imaging studies. Core set of mri acquisitions, joint pathology definitions, and the omeract ra-mri scoring system. J Rheumatol 30:1385–1386PubMed
79.
Zurück zum Zitat van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) Eular definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496PubMedCrossRef van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) Eular definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496PubMedCrossRef
80.
Zurück zum Zitat Härter M (2004) Shared decision making—from the point of view of patients, physicians and health politics is set in place. Z Arztl Fortbild Qualitatssich 98:89–92PubMed Härter M (2004) Shared decision making—from the point of view of patients, physicians and health politics is set in place. Z Arztl Fortbild Qualitatssich 98:89–92PubMed
81.
Zurück zum Zitat Bieber C, Gschwendtner K, Müller N, Eich W (2016) Partizipative entscheidungsfindung (pef)—patient und arzt als team. Psychother Psychosom Med Psychol 66:195–207PubMedCrossRef Bieber C, Gschwendtner K, Müller N, Eich W (2016) Partizipative entscheidungsfindung (pef)—patient und arzt als team. Psychother Psychosom Med Psychol 66:195–207PubMedCrossRef
82.
Zurück zum Zitat Loh A, Simon D, Kriston L, Härter M (2007) Patientenbeteiligung bei medizinischen entscheidungen. Dtsch Arztebl Int 104:1483 Loh A, Simon D, Kriston L, Härter M (2007) Patientenbeteiligung bei medizinischen entscheidungen. Dtsch Arztebl Int 104:1483
83.
Zurück zum Zitat Wiek DBP, Clausen J (2016) Patientenbeteiligung an forschungsprojekten: Die forschungspartner der deutschen rheuma-liga. Z Rheumatol 75:236CrossRef Wiek DBP, Clausen J (2016) Patientenbeteiligung an forschungsprojekten: Die forschungspartner der deutschen rheuma-liga. Z Rheumatol 75:236CrossRef
87.
Zurück zum Zitat Gronning K, Skomsvoll JF, Rannestad T, Steinsbekk A (2012) The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—a randomised controlled trial. Patient Educ Couns 88:113–120PubMedCrossRef Gronning K, Skomsvoll JF, Rannestad T, Steinsbekk A (2012) The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—a randomised controlled trial. Patient Educ Couns 88:113–120PubMedCrossRef
93.
Zurück zum Zitat Niedermann K, Buchi S, Ciurea A, Kubli R, Steurer-Stey C, Villiger PM et al (2012) Six and 12 months’ effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial. Scand J Occup Ther 19:360–369PubMedCrossRef Niedermann K, Buchi S, Ciurea A, Kubli R, Steurer-Stey C, Villiger PM et al (2012) Six and 12 months’ effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial. Scand J Occup Ther 19:360–369PubMedCrossRef
94.
Zurück zum Zitat Pot-Vaucel M, Aubert MP, Guillot P, Glemarec J, Berthelot JM, Le Goff B et al (2016) Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis. Joint Bone Spine 83:199–206PubMedCrossRef Pot-Vaucel M, Aubert MP, Guillot P, Glemarec J, Berthelot JM, Le Goff B et al (2016) Randomised study versus control group of customised therapeutic education for patients in follow-up for rheumatoid arthritis. Joint Bone Spine 83:199–206PubMedCrossRef
95.
Zurück zum Zitat Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927PubMedPubMedCentralCrossRef Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical acr remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295PubMedCrossRef Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical acr remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295PubMedCrossRef
97.
Zurück zum Zitat Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213PubMed Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213PubMed
98.
Zurück zum Zitat Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 72:858–862PubMedCrossRef Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study. Ann Rheum Dis 72:858–862PubMedCrossRef
99.
Zurück zum Zitat Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (hera) study. J Rheumatol 27:623–629PubMed Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M’Seffar A et al (2000) Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (hera) study. J Rheumatol 27:623–629PubMed
100.
Zurück zum Zitat Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the eular recommendations for the management of early arthritis. RMD Open 3:e406PubMedPubMedCentralCrossRef Hua C, Daien CI, Combe B, Landewe R (2017) Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the eular recommendations for the management of early arthritis. RMD Open 3:e406PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW et al (2008) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 61:4–12CrossRef van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Ewals JAPM, Han KH, Hazes JMW et al (2008) Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 61:4–12CrossRef
102.
Zurück zum Zitat Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP (2000) One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 27:2360–2366PubMed Wiles NJ, Dunn G, Barrett EM, Harrison BJ, Silman AJ, Symmons DP (2000) One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline. J Rheumatol 27:2360–2366PubMed
103.
Zurück zum Zitat Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of hla class ii antigens with progression of joint damage. Arthritis Rheum 46:899–905PubMedCrossRef Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW et al (2002) Early and aggressive treatment of rheumatoid arthritis patients affects the association of hla class ii antigens with progression of joint damage. Arthritis Rheum 46:899–905PubMedCrossRef
104.
Zurück zum Zitat Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D (2011) Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the etude et suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 63:1804–1811PubMedCrossRef Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D (2011) Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the etude et suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 63:1804–1811PubMedCrossRef
105.
Zurück zum Zitat Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898PubMedCrossRef Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898PubMedCrossRef
106.
Zurück zum Zitat Soderlin MK, Bergman S (2011) Absent “window of opportunity” in smokers with short disease duration. Data from barfot, a multicenter study of early rheumatoid arthritis. J Rheumatol 38:2160–2168PubMedCrossRef Soderlin MK, Bergman S (2011) Absent “window of opportunity” in smokers with short disease duration. Data from barfot, a multicenter study of early rheumatoid arthritis. J Rheumatol 38:2160–2168PubMedCrossRef
107.
Zurück zum Zitat Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e57PubMedPubMedCentralCrossRef Monti S, Montecucco C, Bugatti S, Caporali R (2015) Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open 1:e57PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–2271PubMedCrossRef van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–2271PubMedCrossRef
111.
Zurück zum Zitat van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432PubMedCrossRef van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424–1432PubMedCrossRef
112.
Zurück zum Zitat Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61:889–894PubMedPubMedCentralCrossRef Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61:889–894PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM et al (2000) Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands. Ann Rheum Dis 59:468–477PubMedPubMedCentralCrossRef van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM et al (2000) Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands. Ann Rheum Dis 59:468–477PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15PubMedCrossRef Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15PubMedCrossRef
115.
Zurück zum Zitat Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M (1996) Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39:996–1005PubMedCrossRef Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M (1996) Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39:996–1005PubMedCrossRef
116.
Zurück zum Zitat Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306PubMedCrossRef Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306PubMedCrossRef
117.
Zurück zum Zitat Tijhuis GJ, Zwinderman AH, Hazes JMW, Van Den Hout WB, Breedveld FC, Vliet Vlieland TPM (2002) A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 47:525–531PubMedCrossRef Tijhuis GJ, Zwinderman AH, Hazes JMW, Van Den Hout WB, Breedveld FC, Vliet Vlieland TPM (2002) A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis. Arthritis Rheum 47:525–531PubMedCrossRef
118.
Zurück zum Zitat Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM (1996) A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 35:475–482PubMedCrossRef Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM (1996) A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 35:475–482PubMedCrossRef
119.
Zurück zum Zitat Vliet Vlieland TP, Breedveld FC, Hazes JM (1997) The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Br J Rheumatol 36:82–85PubMedCrossRef Vliet Vlieland TP, Breedveld FC, Hazes JM (1997) The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Br J Rheumatol 36:82–85PubMedCrossRef
120.
Zurück zum Zitat Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA (1989) Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 32:1505–1514PubMedCrossRef Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA (1989) Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 32:1505–1514PubMedCrossRef
121.
Zurück zum Zitat Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G (1998) Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 316:965–969PubMedPubMedCentralCrossRef Lambert CM, Hurst NP, Forbes JF, Lochhead A, Macleod M, Nuki G (1998) Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 316:965–969PubMedPubMedCentralCrossRef
122.
Zurück zum Zitat Ayhan F (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26:135–144CrossRef Ayhan F (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26:135–144CrossRef
123.
Zurück zum Zitat Bearne LM, Byrne A‑M, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36:311–324PubMedCrossRef Bearne LM, Byrne A‑M, Segrave H, White CM (2016) Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 36:311–324PubMedCrossRef
124.
Zurück zum Zitat van den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM (2003) Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 62:308–315PubMedPubMedCentralCrossRef van den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM (2003) Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 62:308–315PubMedPubMedCentralCrossRef
125.
Zurück zum Zitat de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM (2002) Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 32:196–203PubMedCrossRef de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM (2002) Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 32:196–203PubMedCrossRef
126.
Zurück zum Zitat Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413PubMedCrossRef Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J et al (2011) American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413PubMedCrossRef
127.
Zurück zum Zitat Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 146:406–415PubMedCrossRef Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med 146:406–415PubMedCrossRef
128.
Zurück zum Zitat Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the ticora study): A single-blind randomised controlled trial. Lancet 364:263–269PubMedCrossRef Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the ticora study): A single-blind randomised controlled trial. Lancet 364:263–269PubMedCrossRef
130.
Zurück zum Zitat Kaneko Y, Kondo H, Takeuchi T (2013) American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40:1254–1258PubMedCrossRef Kaneko Y, Kondo H, Takeuchi T (2013) American college of rheumatology/european league against rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. J Rheumatol 40:1254–1258PubMedCrossRef
131.
Zurück zum Zitat Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML et al (2012) Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 acr/eular remission criteria in an observational cohort. Ann Rheum Dis 71:681–686PubMedCrossRef Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML et al (2012) Remission and radiographic outcome in rheumatoid arthritis: Application of the 2011 acr/eular remission criteria in an observational cohort. Ann Rheum Dis 71:681–686PubMedCrossRef
132.
Zurück zum Zitat Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E (2010) Superiority of sdai over das-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultrasonography as a gold standard. Rheumatology 49:683–690PubMedCrossRef Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E (2010) Superiority of sdai over das-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultrasonography as a gold standard. Rheumatology 49:683–690PubMedCrossRef
133.
Zurück zum Zitat Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R (2013) In patients with early rheumatoid arthritis, the new acr/eular definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72:245–249PubMedCrossRef Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R (2013) In patients with early rheumatoid arthritis, the new acr/eular definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 72:245–249PubMedCrossRef
134.
Zurück zum Zitat Kommission bildgebende verfahren der dgrh (2007) Bildgebende verfahren in der rheumatologie. Steinkopff, Darmstadt Kommission bildgebende verfahren der dgrh (2007) Bildgebende verfahren in der rheumatologie. Steinkopff, Darmstadt
135.
Zurück zum Zitat Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343–355PubMedCrossRef Bijlsma JW, Welsing PM, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): A multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388:343–355PubMedCrossRef
138.
Zurück zum Zitat Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al (2014) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The opera study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73:654–661PubMedCrossRef Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P et al (2014) Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The opera study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis 73:654–661PubMedCrossRef
139.
Zurück zum Zitat Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial. Lancet 383:321–332PubMedCrossRef Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P et al (2014) Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial. Lancet 383:321–332PubMedCrossRef
141.
Zurück zum Zitat Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL et al (1996) Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194–199PubMedCrossRef Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL et al (1996) Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 25:194–199PubMedCrossRef
142.
Zurück zum Zitat ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352PubMedCrossRef ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM et al (1996) Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347:347–352PubMedCrossRef
143.
Zurück zum Zitat Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461PubMedCrossRef Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33:1449–1461PubMedCrossRef
144.
Zurück zum Zitat Sokka T, Hannonen P (1999) Utility of disease modifying antirheumatic drugs in “sawtooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58:618–622PubMedPubMedCentralCrossRef Sokka T, Hannonen P (1999) Utility of disease modifying antirheumatic drugs in “sawtooth” strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 58:618–622PubMedPubMedCentralCrossRef
145.
Zurück zum Zitat Capell HA, Murphy EA, Hunter JA (1991) Rheumatoid arthritis: workload and outcome over 10 years. Q J Med 79:461–476PubMed Capell HA, Murphy EA, Hunter JA (1991) Rheumatoid arthritis: workload and outcome over 10 years. Q J Med 79:461–476PubMed
147.
Zurück zum Zitat Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatology 52:99–110PubMedCrossRef Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in ra and their impact on outcome. Rheumatology 52:99–110PubMedCrossRef
148.
Zurück zum Zitat Kleinert S, Krueger K (2011) Kardiovaskuläre komorbidität und ihre risikofaktoren bei rheumatoider arthritis. Z Rheumatol 70:464–472PubMedCrossRef Kleinert S, Krueger K (2011) Kardiovaskuläre komorbidität und ihre risikofaktoren bei rheumatoider arthritis. Z Rheumatol 70:464–472PubMedCrossRef
149.
Zurück zum Zitat Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760PubMedPubMedCentralCrossRef Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760PubMedPubMedCentralCrossRef
150.
Zurück zum Zitat Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis 74:326–332PubMedCrossRef Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis 74:326–332PubMedCrossRef
151.
Zurück zum Zitat Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G et al (2002) Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20:351–358PubMed Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G et al (2002) Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: A randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 20:351–358PubMed
152.
Zurück zum Zitat Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877PubMedCrossRef Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877PubMedCrossRef
153.
Zurück zum Zitat Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26PubMedCrossRef Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19–26PubMedCrossRef
154.
Zurück zum Zitat Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37PubMedCrossRef Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R et al (2006) The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37PubMedCrossRef
155.
Zurück zum Zitat Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A‑M, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474PubMedCrossRef Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A‑M, Walker D et al (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474PubMedCrossRef
156.
Zurück zum Zitat Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-tnf monoclonal antibody, outcome study for the prevention of joint damage in japanese patients with early rheumatoid arthritis: The hopeful 1 study. Ann Rheum Dis 73:536–543PubMedCrossRef Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T et al (2014) Adalimumab, a human anti-tnf monoclonal antibody, outcome study for the prevention of joint damage in japanese patients with early rheumatoid arthritis: The hopeful 1 study. Ann Rheum Dis 73:536–543PubMedCrossRef
158.
Zurück zum Zitat Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in dmard-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from c‑early, a randomised, double-blind, placebo-controlled phase iii study. Ann Rheum Dis 76:96–104PubMedCrossRef Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in dmard-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1‑year results from c‑early, a randomised, double-blind, placebo-controlled phase iii study. Ann Rheum Dis 76:96–104PubMedCrossRef
159.
Zurück zum Zitat Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593PubMedCrossRef Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586–1593PubMedCrossRef
160.
Zurück zum Zitat Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): A randomised, double-blind, parallel treatment trial. Lancet 372:375–382PubMedCrossRef Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (comet): A randomised, double-blind, parallel treatment trial. Lancet 372:375–382PubMedCrossRef
161.
Zurück zum Zitat Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283PubMedCrossRef Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60:2272–2283PubMedCrossRef
162.
Zurück zum Zitat St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443PubMedCrossRef St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443PubMedCrossRef
164.
Zurück zum Zitat Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 75:1081–1091PubMedCrossRef Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: function, a randomised controlled trial. Ann Rheum Dis 75:1081–1091PubMedCrossRef
165.
Zurück zum Zitat Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401–1409PubMedCrossRef Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS et al (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401–1409PubMedCrossRef
166.
Zurück zum Zitat Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the cimestra study. Ann Rheum Dis 67:815–822PubMedCrossRef Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: Second-year clinical and radiographic results from the cimestra study. Ann Rheum Dis 67:815–822PubMedCrossRef
167.
Zurück zum Zitat van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038PubMedCrossRef van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038PubMedCrossRef
168.
Zurück zum Zitat Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-raco trial group. Lancet 353:1568–1573PubMedCrossRef Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. Fin-raco trial group. Lancet 353:1568–1573PubMedCrossRef
169.
Zurück zum Zitat Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA (1994) A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637–643PubMedCrossRef Landewé RB, Goei Thè HS, van Rijthoven AW, Breedveld FC, Dijkmans BA (1994) A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637–643PubMedCrossRef
170.
Zurück zum Zitat Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin a, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819PubMedCrossRef Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin a, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809–1819PubMedCrossRef
171.
Zurück zum Zitat Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082–1088PubMedCrossRef Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 36:1082–1088PubMedCrossRef
172.
Zurück zum Zitat Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225PubMedPubMedCentralCrossRef Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al (1999) Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220–225PubMedPubMedCentralCrossRef
173.
Zurück zum Zitat Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedCrossRef Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedCrossRef
174.
Zurück zum Zitat van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1‑year results of a randomised trial. Lancet 374:459–466PubMedCrossRef van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1‑year results of a randomised trial. Lancet 374:459–466PubMedCrossRef
175.
Zurück zum Zitat Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509PubMedCrossRef Hannonen P, Möttönen T, Hakola M, Oka M (1993) Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501–1509PubMedCrossRef
176.
Zurück zum Zitat Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517PubMedPubMedCentralCrossRef Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517PubMedPubMedCentralCrossRef
177.
Zurück zum Zitat Fleischmann RM, Huizinga TWJ, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e262PubMedPubMedCentralCrossRef Fleischmann RM, Huizinga TWJ, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e262PubMedPubMedCentralCrossRef
178.
Zurück zum Zitat Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386PubMedCrossRef Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386PubMedCrossRef
187.
Zurück zum Zitat Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39:616–622PubMedCrossRef Fries JF, Williams CA, Morfeld D, Singh G, Sibley J (1996) Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 39:616–622PubMedCrossRef
188.
Zurück zum Zitat Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173–1177PubMedCrossRef Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173–1177PubMedCrossRef
189.
Zurück zum Zitat Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21PubMedCrossRef Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14–21PubMedCrossRef
190.
Zurück zum Zitat Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin a, sulphasalazine) or monotherapy for three years. Rheumatology 41:892–898PubMedCrossRef Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin a, sulphasalazine) or monotherapy for three years. Rheumatology 41:892–898PubMedCrossRef
191.
Zurück zum Zitat Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060–1068PubMedCrossRef Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060–1068PubMedCrossRef
192.
Zurück zum Zitat Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204PubMedCrossRef Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41:196–204PubMedCrossRef
193.
Zurück zum Zitat Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of carera, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520PubMedCrossRef Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of carera, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511–520PubMedCrossRef
194.
Zurück zum Zitat Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665PubMedCrossRef Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665PubMedCrossRef
195.
Zurück zum Zitat Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733PubMedCrossRef Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733PubMedCrossRef
196.
Zurück zum Zitat Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353:259–266PubMedCrossRef Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353:259–266PubMedCrossRef
197.
Zurück zum Zitat Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med 159:2542–2550PubMedCrossRef Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch Intern Med 159:2542–2550PubMedCrossRef
198.
Zurück zum Zitat Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450PubMedCrossRef Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450PubMedCrossRef
199.
Zurück zum Zitat Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved sf-36 scores and reduced the effect of rheumatoid arthritis (ra) on work activity for patients with early ra. J Rheumatol 35:206–215PubMed Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved sf-36 scores and reduced the effect of rheumatoid arthritis (ra) on work activity for patients with early ra. J Rheumatol 35:206–215PubMed
200.
Zurück zum Zitat Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134PubMedCrossRef Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134PubMedCrossRef
201.
Zurück zum Zitat Sarzi-Puttini P, D’Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL et al (2005) An open, randomized comparison study of cyclosporine a, cyclosporine a + methotrexate and cyclosporine a + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15–22PubMedCrossRef Sarzi-Puttini P, D’Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL et al (2005) An open, randomized comparison study of cyclosporine a, cyclosporine a + methotrexate and cyclosporine a + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15–22PubMedCrossRef
202.
Zurück zum Zitat Gerards AH, Landewé RBM, Prins APA, Bruyn GW, Goei Thé HS, Laan RFJM et al (2003) Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291–296PubMedPubMedCentralCrossRef Gerards AH, Landewé RBM, Prins APA, Bruyn GW, Goei Thé HS, Laan RFJM et al (2003) Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291–296PubMedPubMedCentralCrossRef
203.
Zurück zum Zitat Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42:1545–1549PubMedCrossRef Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: A 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42:1545–1549PubMedCrossRef
204.
Zurück zum Zitat Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R et al (2007) Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56:3919–3927PubMedCrossRef Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R et al (2007) Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56:3919–3927PubMedCrossRef
205.
Zurück zum Zitat Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722PubMedCrossRef Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E et al (2006) Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 54:716–722PubMedCrossRef
206.
Zurück zum Zitat Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The comet trial. Ann Rheum Dis 69:222–225PubMedCrossRef Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A et al (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The comet trial. Ann Rheum Dis 69:222–225PubMedCrossRef
207.
Zurück zum Zitat Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination dmard therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98PubMedCrossRef Ma MH, Kingsley GH, Scott DL (2010) A systematic comparison of combination dmard therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 49:91–98PubMedCrossRef
208.
Zurück zum Zitat Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (mtx) monotherapy versus mtx combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112PubMedCrossRef Katchamart W, Trudeau J, Phumethum V, Bombardier C (2009) Efficacy and toxicity of methotrexate (mtx) monotherapy versus mtx combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112PubMedCrossRef
209.
210.
Zurück zum Zitat Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD et al (2008) Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317PubMedCrossRef Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD et al (2008) Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317PubMedCrossRef
211.
Zurück zum Zitat Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al (2007) Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled mascot study. Ann Rheum Dis 66:235–241PubMedCrossRef Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al (2007) Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled mascot study. Ann Rheum Dis 66:235–241PubMedCrossRef
212.
Zurück zum Zitat Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656–663PubMedCrossRef Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L et al (2008) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656–663PubMedCrossRef
213.
Zurück zum Zitat Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B et al (2006) Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: A 2004 proposal of the french society of rheumatology. Ann Rheum Dis 65:45–50PubMedCrossRef Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B et al (2006) Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: A 2004 proposal of the french society of rheumatology. Ann Rheum Dis 65:45–50PubMedCrossRef
215.
Zurück zum Zitat Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M (2006) Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 65:1449–1455PubMedPubMedCentralCrossRef Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M (2006) Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 65:1449–1455PubMedPubMedCentralCrossRef
216.
Zurück zum Zitat Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M et al (2018) S2e-leitlinie: Therapie der rheumatoiden arthritis mit krankheitsmodifizierenden medikamenten. Z Rheumatol 77:35–53PubMedCrossRef Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M et al (2018) S2e-leitlinie: Therapie der rheumatoiden arthritis mit krankheitsmodifizierenden medikamenten. Z Rheumatol 77:35–53PubMedCrossRef
217.
Zurück zum Zitat Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117–1125PubMedCrossRef Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117–1125PubMedCrossRef
218.
Zurück zum Zitat van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524PubMedCrossRef van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524PubMedCrossRef
220.
Zurück zum Zitat Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA (2017) Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 15(3):133–139PubMedCrossRef Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA (2017) Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 15(3):133–139PubMedCrossRef
221.
Zurück zum Zitat Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef
222.
Zurück zum Zitat Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological dmards: A systematic literature review informing the 2016 update of the eular recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136PubMedCrossRef Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological dmards: A systematic literature review informing the 2016 update of the eular recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101–1136PubMedCrossRef
223.
Zurück zum Zitat Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic dmards. Ann Rheum Dis 76:504–510PubMedCrossRef Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic dmards. Ann Rheum Dis 76:504–510PubMedCrossRef
224.
Zurück zum Zitat Krüger K, Albrecht K, Rehart S, Scholz R, der Kommission Pharmakotherapie D (2014) Recommendations of the german society for rheumatology on the perioperative approach under therapy with dmards and biologicals in inflammatory rheumatic diseases. Z Rheumatol 73:77–84PubMedCrossRef Krüger K, Albrecht K, Rehart S, Scholz R, der Kommission Pharmakotherapie D (2014) Recommendations of the german society for rheumatology on the perioperative approach under therapy with dmards and biologicals in inflammatory rheumatic diseases. Z Rheumatol 73:77–84PubMedCrossRef
225.
Zurück zum Zitat Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714PubMed Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714PubMed
226.
Zurück zum Zitat Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317:180–181PubMedPubMedCentralCrossRef Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 317:180–181PubMedPubMedCentralCrossRef
227.
Zurück zum Zitat Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRef Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRef
228.
Zurück zum Zitat Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRef Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRef
229.
Zurück zum Zitat Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149–156PubMedCrossRef Maneiro JR, Souto A, Gomez-Reino JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149–156PubMedCrossRef
230.
Zurück zum Zitat Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189PubMedCrossRef Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189PubMedCrossRef
231.
Zurück zum Zitat Wadström H, Frisell T, Askling J, The Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from sweden. JAMA Intern Med 177:1605PubMedPubMedCentralCrossRef Wadström H, Frisell T, Askling J, The Anti-Rheumatic Therapy in Sweden Study G (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from sweden. JAMA Intern Med 177:1605PubMedPubMedCentralCrossRef
232.
Zurück zum Zitat Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 38:6–12PubMedCrossRef Laan RF, Jansen TL, van Riel PL (1999) Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology 38:6–12PubMedCrossRef
233.
Zurück zum Zitat Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818PubMedPubMedCentralCrossRef Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818PubMedPubMedCentralCrossRef
235.
Zurück zum Zitat ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the cobra-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240PubMed ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D et al (2015) Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1‑year results of the cobra-light open-label, randomised, non-inferiority trial. Ann Rheum Dis 74:1233–1240PubMed
236.
Zurück zum Zitat Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. Lancet 371:205–214PubMedCrossRef Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E et al (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. Lancet 371:205–214PubMedCrossRef
237.
Zurück zum Zitat Gestel AMV, Laan RFJM, Haagsma CJ, Van De Putte LBA, Van Riel PLCM (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Baillieres Clin Rheumatol 34:347–351 Gestel AMV, Laan RFJM, Haagsma CJ, Van De Putte LBA, Van Riel PLCM (1995) Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Baillieres Clin Rheumatol 34:347–351
238.
Zurück zum Zitat Million R, Kellgren JH, Poole P, Jayson MI (1984) Long-term study of management of rheumatoid arthritis. Lancet 1:812–816PubMedCrossRef Million R, Kellgren JH, Poole P, Jayson MI (1984) Long-term study of management of rheumatoid arthritis. Lancet 1:812–816PubMedCrossRef
239.
Zurück zum Zitat Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in british patients with rheumatoid arthritis. Br J Rheumatol 25:206–209PubMedCrossRef Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in british patients with rheumatoid arthritis. Br J Rheumatol 25:206–209PubMedCrossRef
240.
Zurück zum Zitat Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146PubMedCrossRef Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146PubMedCrossRef
241.
Zurück zum Zitat Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977PubMedCrossRef Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977PubMedCrossRef
242.
Zurück zum Zitat Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936PubMedCrossRef Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936PubMedCrossRef
244.
Zurück zum Zitat van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12PubMedCrossRef van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12PubMedCrossRef
245.
Zurück zum Zitat Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339PubMedCrossRef Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329–339PubMedCrossRef
246.
Zurück zum Zitat McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213PubMed McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213PubMed
247.
Zurück zum Zitat Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med 103:31S–39SPubMedCrossRef Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. Am J Med 103:31S–39SPubMedCrossRef
248.
Zurück zum Zitat Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123PubMedCrossRef Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123PubMedCrossRef
249.
Zurück zum Zitat Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMedCrossRef
250.
Zurück zum Zitat Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an eular task force. Ann Rheum Dis 75:952–957PubMedCrossRef Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an eular task force. Ann Rheum Dis 75:952–957PubMedCrossRef
251.
Zurück zum Zitat Seror P, Pluvinage P, d’Andre FL, Benamou P, Attuil G (1999) Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in france). Rheumatology 38:1272–1274PubMedCrossRef Seror P, Pluvinage P, d’Andre FL, Benamou P, Attuil G (1999) Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in france). Rheumatology 38:1272–1274PubMedCrossRef
252.
Zurück zum Zitat Weitoft T, Uddenfeldt P (2000) Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 59:233–235PubMedPubMedCentralCrossRef Weitoft T, Uddenfeldt P (2000) Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis 59:233–235PubMedPubMedCentralCrossRef
253.
Zurück zum Zitat Chakravarty K, Pharoah PD, Scott DG (1994) A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 33:464–468PubMedCrossRef Chakravarty K, Pharoah PD, Scott DG (1994) A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 33:464–468PubMedCrossRef
255.
Zurück zum Zitat Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324:1716–1725PubMedCrossRef Brooks PM, Day RO (1991) Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med 324:1716–1725PubMedCrossRef
256.
Zurück zum Zitat Furst DE (1994) Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1–9PubMedCrossRef Furst DE (1994) Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1–9PubMedCrossRef
257.
Zurück zum Zitat van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase‑2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther 17:66PubMedPubMedCentralCrossRef van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase‑2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: A network meta-analysis. Arthritis Res Ther 17:66PubMedPubMedCentralCrossRef
258.
Zurück zum Zitat Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008872.pub2 CrossRefPubMed Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. https://​doi.​org/​10.​1002/​14651858.​CD008872.​pub2 CrossRefPubMed
259.
Zurück zum Zitat Nsaids GPC (2010) BMJ clinical evidence 2010 Nsaids GPC (2010) BMJ clinical evidence 2010
260.
Zurück zum Zitat Hardin JG Jr., Kirk KA (1979) Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. J Rheumatol 6:405–412PubMed Hardin JG Jr., Kirk KA (1979) Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis. J Rheumatol 6:405–412PubMed
262.
Zurück zum Zitat Seideman P, Melander A (1988) Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 27:117–122PubMedCrossRef Seideman P, Melander A (1988) Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 27:117–122PubMedCrossRef
264.
Zurück zum Zitat Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ (2015) Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 19:1213–1223PubMedCrossRef Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ (2015) Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 19:1213–1223PubMedCrossRef
267.
Zurück zum Zitat Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594PubMedPubMedCentralCrossRef Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589–1594PubMedPubMedCentralCrossRef
268.
Zurück zum Zitat Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM (1998) A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 25:231–237PubMed Bell MJ, Lineker SC, Wilkins AL, Goldsmith CH, Badley EM (1998) A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis. J Rheumatol 25:231–237PubMed
269.
Zurück zum Zitat Mayoux Benhamou MA (2007) Reconditioning in patients with rheumatoid arthritis. Ann Readapt Med Phys 50:382–5, 77–81PubMedCrossRef Mayoux Benhamou MA (2007) Reconditioning in patients with rheumatoid arthritis. Ann Readapt Med Phys 50:382–5, 77–81PubMedCrossRef
270.
Zurück zum Zitat Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM et al (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 47:239–248PubMedCrossRef Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Treharne GJ, Panoulas VF, Douglas KM et al (2008) Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. Rheumatology 47:239–248PubMedCrossRef
271.
Zurück zum Zitat Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56:617–635PubMedCrossRef Neill J, Belan I, Ried K (2006) Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56:617–635PubMedCrossRef
272.
Zurück zum Zitat Wessel J (2004) The effectiveness of hand exercises for persons with rheumatoid arthritis: a systematic review. J Hand Ther 17:174–180PubMedCrossRef Wessel J (2004) The effectiveness of hand exercises for persons with rheumatoid arthritis: a systematic review. J Hand Ther 17:174–180PubMedCrossRef
273.
Zurück zum Zitat Eversden L, Maggs F, Nightingale P, Jobanputra P (2007) A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 8:23PubMedPubMedCentralCrossRef Eversden L, Maggs F, Nightingale P, Jobanputra P (2007) A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord 8:23PubMedPubMedCentralCrossRef
275.
Zurück zum Zitat Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R et al (2010) Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res 62:984–992CrossRef Baillet A, Zeboulon N, Gossec L, Combescure C, Bodin LA, Juvin R et al (2010) Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res 62:984–992CrossRef
276.
Zurück zum Zitat Bulthuis Y, Drossaers-Bakker KW, Taal E, Rasker J, Oostveen J, van’t Pad Bosch P et al (2007) Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge. Baillieres Clin Rheumatol 46:1712–1717 Bulthuis Y, Drossaers-Bakker KW, Taal E, Rasker J, Oostveen J, van’t Pad Bosch P et al (2007) Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge. Baillieres Clin Rheumatol 46:1712–1717
277.
Zurück zum Zitat Bulthuis Y, Mohammad S, Braakman-Jansen LM, Drossaers-Bakker KW, van de Laar MA (2008) Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: Results of a randomized controlled clinical trial. Arthritis Rheum 59:247–254PubMedCrossRef Bulthuis Y, Mohammad S, Braakman-Jansen LM, Drossaers-Bakker KW, van de Laar MA (2008) Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: Results of a randomized controlled clinical trial. Arthritis Rheum 59:247–254PubMedCrossRef
278.
Zurück zum Zitat Gaudin P, Leguen-Guegan S, Allenet B, Baillet A, Grange L, Juvin R (2008) Is dynamic exercise beneficial in patients with rheumatoid arthritis? Joint Bone Spine 75:11–17PubMedCrossRef Gaudin P, Leguen-Guegan S, Allenet B, Baillet A, Grange L, Juvin R (2008) Is dynamic exercise beneficial in patients with rheumatoid arthritis? Joint Bone Spine 75:11–17PubMedCrossRef
279.
Zurück zum Zitat Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK et al (2007) Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 57:943–952PubMedCrossRef Neuberger GB, Aaronson LS, Gajewski B, Embretson SE, Cagle PE, Loudon JK et al (2007) Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. Arthritis Rheum 57:943–952PubMedCrossRef
280.
Zurück zum Zitat Plasqui G (2008) The role of physical activity in rheumatoid arthritis. Physiol Behav 94:270–275PubMedCrossRef Plasqui G (2008) The role of physical activity in rheumatoid arthritis. Physiol Behav 94:270–275PubMedCrossRef
281.
Zurück zum Zitat Cairns AP, McVeigh JG (2009) A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int 30:147–158PubMedCrossRef Cairns AP, McVeigh JG (2009) A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int 30:147–158PubMedCrossRef
282.
Zurück zum Zitat Hsieh LF, Chen SC, Chuang CC, Chai HM, Chen WS, He YC (2009) Supervised aerobic exercise is more effective than home aerobic exercise in female chinese patients with rheumatoid arthritis. J Rehabil Med 41:332–337PubMedCrossRef Hsieh LF, Chen SC, Chuang CC, Chai HM, Chen WS, He YC (2009) Supervised aerobic exercise is more effective than home aerobic exercise in female chinese patients with rheumatoid arthritis. J Rehabil Med 41:332–337PubMedCrossRef
283.
Zurück zum Zitat Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende Els CHM (2009) Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009 (4):CD006853. https://doi.org/10.1002/14651858.CD006853.pub2 Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende Els CHM (2009) Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009 (4):CD006853. https://​doi.​org/​10.​1002/​14651858.​CD006853.​pub2
284.
Zurück zum Zitat Balsamo S, Diniz LR, dos Santos-Neto LL, da Mota LM (2014) Exercise and fatigue in rheumatoid arthritis. Isr Med Assoc J 16:57–60PubMed Balsamo S, Diniz LR, dos Santos-Neto LL, da Mota LM (2014) Exercise and fatigue in rheumatoid arthritis. Isr Med Assoc J 16:57–60PubMed
285.
Zurück zum Zitat Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: A systematic review. Musculoskelet Care 11:238–247CrossRef Cramp F, Berry J, Gardiner M, Smith F, Stephens D (2013) Health behaviour change interventions for the promotion of physical activity in rheumatoid arthritis: A systematic review. Musculoskelet Care 11:238–247CrossRef
288.
Zurück zum Zitat de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH et al (2003) Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2415–2424PubMedCrossRef de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH et al (2003) Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 48:2415–2424PubMedCrossRef
289.
Zurück zum Zitat van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, van der Giesen FJ, Breedveld FC et al (2006) Using internet technology to deliver a home-based physical activity intervention for patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 55:935–945PubMedCrossRef van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, van der Giesen FJ, Breedveld FC et al (2006) Using internet technology to deliver a home-based physical activity intervention for patients with rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 55:935–945PubMedCrossRef
291.
Zurück zum Zitat Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, De Bie R et al (2015) Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of cochrane systematic review. Eur J Phys Rehabil Med 51:833–847PubMed Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, De Bie R et al (2015) Balneotherapy (or spa therapy) for rheumatoid arthritis. An abridged version of cochrane systematic review. Eur J Phys Rehabil Med 51:833–847PubMed
294.
Zurück zum Zitat Hirvonen HE, Mikkelsson MK, Kautiainen H, Pohjolainen TH, Leirisalo-Repo M (2006) Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol 24:295–301PubMed Hirvonen HE, Mikkelsson MK, Kautiainen H, Pohjolainen TH, Leirisalo-Repo M (2006) Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol 24:295–301PubMed
297.
Zurück zum Zitat Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J (2010) Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized double-blind controlled trial. Clin Rheumatol 29:501–509PubMedCrossRef Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J (2010) Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: A randomized double-blind controlled trial. Clin Rheumatol 29:501–509PubMedCrossRef
300.
Zurück zum Zitat Evans S, Moieni M, Lung K, Tsao J, Sternlieb B, Taylor M et al (2013) Impact of iyengar yoga on quality of life in young women with rheumatoid arthritis. Clin J Pain 29:988–997PubMedPubMedCentralCrossRef Evans S, Moieni M, Lung K, Tsao J, Sternlieb B, Taylor M et al (2013) Impact of iyengar yoga on quality of life in young women with rheumatoid arthritis. Clin J Pain 29:988–997PubMedPubMedCentralCrossRef
304.
Zurück zum Zitat Lee MS, Pittler MH, Ernst E (2007) Tai chi for rheumatoid arthritis: Systematic review. Rheumatology 46:1648–1651PubMedCrossRef Lee MS, Pittler MH, Ernst E (2007) Tai chi for rheumatoid arthritis: Systematic review. Rheumatology 46:1648–1651PubMedCrossRef
305.
Zurück zum Zitat Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005) Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 19:247–254PubMedCrossRef Steultjens EM, Dekker J, Bouter LM, Leemrijse CJ, van den Ende CH (2005) Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 19:247–254PubMedCrossRef
306.
Zurück zum Zitat Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH (2002) Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 47:672–685PubMedCrossRef Steultjens EM, Dekker J, Bouter LM, van Schaardenburg D, van Kuyk MA, van den Ende CH (2002) Occupational therapy for rheumatoid arthritis: a systematic review. Arthritis Rheum 47:672–685PubMedCrossRef
307.
Zurück zum Zitat Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M et al (2015) Exercises to improve function of the rheumatoid hand (sarah): A randomised controlled trial. Lancet 385:421–429PubMedCrossRef Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M et al (2015) Exercises to improve function of the rheumatoid hand (sarah): A randomised controlled trial. Lancet 385:421–429PubMedCrossRef
311.
Zurück zum Zitat Baldwin D, Johnstone B, Ge B, Hewett J, Smith M, Sharp G (2012) Randomized prospective study of a work place ergonomic intervention for individuals with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 64:1527–1535CrossRef Baldwin D, Johnstone B, Ge B, Hewett J, Smith M, Sharp G (2012) Randomized prospective study of a work place ergonomic intervention for individuals with rheumatoid arthritis and osteoarthritis. Arthritis Care Res 64:1527–1535CrossRef
313.
Zurück zum Zitat Conceicao CS, Gomes Neto M, Mendes SM, Sa KN, Baptista AF (2015) Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. Disabil Rehabil 37:1209–1213CrossRefPubMed Conceicao CS, Gomes Neto M, Mendes SM, Sa KN, Baptista AF (2015) Systematic review and meta-analysis of effects of foot orthoses on pain and disability in rheumatoid arthritis patients. Disabil Rehabil 37:1209–1213CrossRefPubMed
315.
Zurück zum Zitat Hennessy K, Woodburn J, Steultjens MP (2012) Custom foot orthoses for rheumatoid arthritis: a systematic review. Arthritis Care Res 64:311–320CrossRef Hennessy K, Woodburn J, Steultjens MP (2012) Custom foot orthoses for rheumatoid arthritis: a systematic review. Arthritis Care Res 64:311–320CrossRef
319.
Zurück zum Zitat Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B (2002) Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291–302PubMedCrossRef Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B (2002) Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 47:291–302PubMedCrossRef
320.
Zurück zum Zitat Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP (2007) Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychol 26:241–250PubMedCrossRef Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP (2007) Psychological interventions for arthritis pain management in adults: A meta-analysis. Health Psychol 26:241–250PubMedCrossRef
321.
Zurück zum Zitat Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ (2002) Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. Pain 100:141–153PubMedCrossRef Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ (2002) Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: A randomized controlled trial. Pain 100:141–153PubMedCrossRef
322.
Zurück zum Zitat Savelkoul M, de Witte L, Post M (2003) Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 50:133–143PubMedCrossRef Savelkoul M, de Witte L, Post M (2003) Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 50:133–143PubMedCrossRef
323.
Zurück zum Zitat Sharpe L, Allard S, Sensky T (2008) Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 59:311–316PubMedCrossRef Sharpe L, Allard S, Sensky T (2008) Five-year followup of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 59:311–316PubMedCrossRef
324.
Zurück zum Zitat Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S (2003) Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology 42:435–441PubMedCrossRef Sharpe L, Sensky T, Timberlake N, Ryan B, Allard S (2003) Long-term efficacy of a cognitive behavioural treatment from a randomized controlled trial for patients recently diagnosed with rheumatoid arthritis. Rheumatology 42:435–441PubMedCrossRef
330.
Zurück zum Zitat Lee MS, Shin BC, Ernst E (2008) Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology 47:1747–1753PubMedCrossRef Lee MS, Shin BC, Ernst E (2008) Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology 47:1747–1753PubMedCrossRef
331.
Zurück zum Zitat Wang C, de Pablo P, Chen X, Schmid C, McAlindon T (2008) Acupuncture for pain relief in patients with rheumatoid arthritis: A systematic review. Arthritis Rheum 59:1249–1256PubMedCrossRef Wang C, de Pablo P, Chen X, Schmid C, McAlindon T (2008) Acupuncture for pain relief in patients with rheumatoid arthritis: A systematic review. Arthritis Rheum 59:1249–1256PubMedCrossRef
332.
Zurück zum Zitat Park J, Ernst E (2005) Ayurvedic medicine for rheumatoid arthritis: A systematic review. Semin Arthritis Rheum 34:705–713PubMedCrossRef Park J, Ernst E (2005) Ayurvedic medicine for rheumatoid arthritis: A systematic review. Semin Arthritis Rheum 34:705–713PubMedCrossRef
334.
Zurück zum Zitat Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: A systematic review. Rheumatology 50:1672–1683PubMedCrossRef Macfarlane GJ, El-Metwally A, De Silva V, Ernst E, Dowds GL, Moots RJ (2011) Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: A systematic review. Rheumatology 50:1672–1683PubMedCrossRef
335.
Zurück zum Zitat Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L, Luo CG et al (2016) Tripterygium wilfordii hook f versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: A systematic review and network meta-analysis. BMC Complement Altern Med 16:215PubMedPubMedCentralCrossRef Wang HL, Jiang Q, Feng XH, Zhang HD, Ge L, Luo CG et al (2016) Tripterygium wilfordii hook f versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: A systematic review and network meta-analysis. BMC Complement Altern Med 16:215PubMedPubMedCentralCrossRef
336.
Zurück zum Zitat Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C et al (2017) Treatment of rheumatoid arthritis with combination of methotrexate and tripterygium wilfordii: a meta-analysis. Life Sci 171:45–50PubMedCrossRef Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C et al (2017) Treatment of rheumatoid arthritis with combination of methotrexate and tripterygium wilfordii: a meta-analysis. Life Sci 171:45–50PubMedCrossRef
337.
Zurück zum Zitat Zhang W, Shi Q, Zhao LD, Li Y, Tang FL, Zhang FC et al (2010) The safety and effectiveness of a chloroform/methanol extract of tripterygium wilfordii hook f (t2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol 16:375–378PubMedCrossRef Zhang W, Shi Q, Zhao LD, Li Y, Tang FL, Zhang FC et al (2010) The safety and effectiveness of a chloroform/methanol extract of tripterygium wilfordii hook f (t2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol 16:375–378PubMedCrossRef
340.
Zurück zum Zitat Jiang J, Li K, Wang F, Yang B, Fu Y, Zheng J et al (2016) Effect of marine-derived n‑3 polyunsaturated fatty acids on major eicosanoids: a systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE 11:e147351PubMedPubMedCentralCrossRef Jiang J, Li K, Wang F, Yang B, Fu Y, Zheng J et al (2016) Effect of marine-derived n‑3 polyunsaturated fatty acids on major eicosanoids: a systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE 11:e147351PubMedPubMedCentralCrossRef
344.
Zurück zum Zitat Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M et al (2015) Fish oil in recent onset rheumatoid arthritis: A randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74:89–95PubMedCrossRef Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M et al (2015) Fish oil in recent onset rheumatoid arthritis: A randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74:89–95PubMedCrossRef
345.
Zurück zum Zitat Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
346.
Zurück zum Zitat Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257PubMedCrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42:244–257PubMedCrossRef
347.
Zurück zum Zitat Aletaha D, Smolen J (2005) The simplified disease activity index (sdai) and the clinical disease activity index (cdai): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108PubMed Aletaha D, Smolen J (2005) The simplified disease activity index (sdai) and the clinical disease activity index (cdai): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108PubMed
Metadaten
Titel
Management der frühen rheumatoiden Arthritis
Interdisziplinäre Leitlinie
verfasst von
Prof. Dr. M. Schneider
G. Baseler
O. Funken
S. Heberger
U. Kiltz
P. Klose
K. Krüger
J. Langhorst
W. Mau
R. Oltman
B. Richter
S. Seitz
P. Sewerin
R. Tholen
C. Weseloh
Univ.-Prof. Dr. M. Witthöft
C. Specker
Publikationsdatum
01.06.2020
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-020-00775-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Degenerierte Bioklappe: Ist Reoperation oder TAVI hier die bessere Option?

13.06.2024 TAVI Nachrichten

Im Fall eines Bioprothesen-Versagens nach Aortenklappenersatz kann ein notwendiger Revisionseingriff heute operativ oder kathetergestützt als Valve-in-Valve-TAVI vorgenommen werden. Eine Beobachtungsstudie lieferte neue Daten zum Vergleich beider Optionen.

Fortgeschrittenes Ovarial-Ca.: Unverdächtige Lymphknoten entfernen?

13.06.2024 ASCO 2024 Kongressbericht

Beim fortgeschrittenen Ovarialkarzinom und klinisch verdächtigen Lymphknoten in der Debulking-Op. ist die abdominale retroperitoneale Lymphadenektomie (RPL) Standard. Ohne verdächtige Lymphknoten ist der Nutzen fraglich.

Krillöl hilft nicht gegen Kniearthrose

13.06.2024 Arthrosen Nachrichten

Mit Krillöl zur Nahrungsergänzung lassen sich Schmerzen und Entzündungen bei Kniearthrose nicht stärker lindern als unter Placebo. Das hat eine kontrollierte Studie mit über 260 Betroffenen ergeben.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.